Patent ID: 8232281
Filing Date: 2012-07-31
Classification: A61K,A61P,Y10S

Abstract:
1. A method of reducing the risk of a macrovascular complication in the treatment of patients who have been diagnosed with manifest type 2 diabetes comprising the steps of preparing an oral medicament comprising 1-[(4-methyl -quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl) -xanthine or one of the salts thereof, and administering said oral medicament to said patient, wherein the oral medicament is a tablet and the amount of said 1-[(4-methyl -quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl) -xanthine administered to said patient is 0.5 mg, 1 mg, 2.5 mg, 5 mg, or 10 mg, and wherein the macrovascular complication is myocardial infarction, acute coronary syndrome, unstable angina pectoris, stable angina pectoris, haemorrhagic or ischaemic stroke, peripheral arterial occlusive disease, cardiomyopathy, left heart insufficiency, right heart insufficiency, global heart failure, heart rhythm disorders, or vascular restenosis.